{
    "clinical_study": {
        "@rank": "31938", 
        "arm_group": [
            {
                "arm_group_label": "HPV Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Subjects who were aged 9-14 years at study entry and received two doses of the HPV-16/18 vaccine according to a 0,6-months schedule in the study HPV-048 PRI (NCT00541970)."
            }, 
            {
                "arm_group_label": "HPV Group 2", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects who were aged 15-25 years at study entry and received three doses of the HPV 16/18 vaccine according to a 0,1,6-months schedule in the study HPV-048 PRI (NCT00541970)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to establish the long-term persistence of the immune response\n      and safety of the HPV vaccine in healthy females who were aged 9 to 25 years in the primary\n      study (NCT00541970)."
        }, 
        "brief_title": "Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Infections, Papillomavirus", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who, in the opinion of the investigator, can and will comply with the\n             requirements of the protocol or subjects' parent(s)/Legally Acceptable\n             Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will\n             comply, with the requirements of the protocol.\n\n          -  Subjects who completed their primary vaccination and received either two or three\n             doses of GSK Biologicals' HPV-16/18 vaccine according to a 0,6-months schedule or a\n             0,1,6-months schedule in the study HPV-048 PRI (110659) (NCT00541970).\n\n          -  A female between, and including, 9 and 14 years of age or 15 and 25 years of age, at\n             the time of first vaccination, depending on which group they belonged to in the study\n             HPV-048 PRI (110659) (NCT00541970), i.e., 9-14 year old subjects should have received\n             two doses of GSK Biologicals' HPV-16/18 vaccine according to a 0,6-months schedule\n             and 15-25 year old subjects should have received three doses of GSK Biologicals'\n             HPV-16/18 vaccine  according to a 0,1,6-months schedule.\n\n          -  Written informed consent obtained from the subject/from the parent(s)/LAR(s) of the\n             subject. In addition, subjects below the legal age of consent should sign and\n             personally date a written informed assent form.\n\n          -  Healthy subjects as established by medical history and clinical examination before\n             entering into the study.\n\n        Exclusion Criteria:\n\n          -  Child in care.\n\n          -  Use of any investigational or non-registered product (drug or vaccine) other than the\n             HPV-16/18 study vaccine administered in the study HPV-048 PRI (110659) (NCT00541970)\n             from the last visit of the primary study up to the current study visit or planned use\n             during the study period.\n\n          -  Administration of any HPV vaccine from the last visit of the primary study up to the\n             current study visit or planned use during the study period.\n\n          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants\n             or other immune-modifying drugs within three months prior to blood sampling. Inhaled\n             and topical steroids are allowed.\n\n          -  Planned administration/administration of a vaccine not foreseen by the study protocol\n             within the period starting 30 days before study entry, with the exception of routine\n             meningococcal, inactivated influenza, hepatitis B, diphtheria/tetanus and/or\n             diphtheria/tetanus-containing, poliomyelitis and/or pertussis vaccines up to 8 days\n             before study entry. Enrolment will be deferred until the subject is outside of\n             specified window.\n\n          -  Concurrently participating in another clinical study, at any time during the study\n             period, in which the subject has been or will be exposed to an investigational or a\n             non-investigational vaccine/product.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination.\n\n          -  Cancer or autoimmune disease under treatment.\n\n          -  Administration of immunoglobulins and/or any blood products within the 3 months\n             preceding the blood sampling."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "32 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100618", 
            "org_study_id": "200255", 
            "secondary_id": "2014-000060-17"
        }, 
        "intervention": {
            "arm_group_label": [
                "HPV Group 1", 
                "HPV Group 2"
            ], 
            "description": "Blood samples will be collected from all subjects at Year 6.5", 
            "intervention_name": "Blood sampling", 
            "intervention_type": "Procedure", 
            "other_name": "Cervarix\u2122"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "6.5 years", 
            "Safety", 
            "Human Papillomavirus (HPV) vaccine", 
            "Immunogenicity", 
            "Adolescents", 
            "Adults", 
            "Antibody persistence"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "number_of_arms": "2", 
        "official_title": "Evaluation of Antibody Persistence for GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul Ehrlich Institute"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Evaluation of immune persistence in terms of antibody titres", 
            "safety_issue": "No", 
            "time_frame": "6.5 years after first vaccination with HPV-16/18 administered in the study HPV-048 PRI (NCT00541970)"
        }, 
        "removed_countries": {
            "country": "Germany"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100618"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Evaluation of immunogenicity in terms of seroconversion rates (SCRs) and antibody titres", 
                "safety_issue": "No", 
                "time_frame": "6.5 years after first vaccination with HPV-16/18 (20 \u00b5g of each antigen) administered in the study HPV-048 PRI (NCT00541970)"
            }, 
            {
                "measure": "Occurrence of SAEs", 
                "safety_issue": "No", 
                "time_frame": "After primary study completion (Month 60) up to end of the study (Visit 1 at Year 6.5)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}